BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 14705216)

  • 1. Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis.
    Lard LR; Roep BO; Toes RE; Huizinga TW
    J Rheumatol; 2004 Jan; 31(1):35-9. PubMed ID: 14705216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 10 (IL-10), not IL-4 or interferon-gamma production, correlates with progression of joint destruction in rheumatoid arthritis.
    Verhoef CM; van Roon JA; Vianen ME; Bijlsma JW; Lafeber FP
    J Rheumatol; 2001 Sep; 28(9):1960-6. PubMed ID: 11550960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis.
    Welsing PM; van Gestel AM; Swinkels HL; Kiemeney LA; van Riel PL
    Arthritis Rheum; 2001 Sep; 44(9):2009-17. PubMed ID: 11592361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease.
    Chen DY; Hsieh TY; Chen YM; Hsieh CW; Lan JL; Lin FJ
    Gerontology; 2009; 55(3):250-8. PubMed ID: 18849599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis.
    Lard LR; van Gaalen FA; Schonkeren JJ; Pieterman EJ; Stoeken G; Vos K; Nelissen RG; Westendorp RG; Hoeben RC; Breedveld FC; Toes RE; Huizinga TW
    Arthritis Rheum; 2003 Jul; 48(7):1841-8. PubMed ID: 12847677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N; Juillet F; Garnero P
    Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis.
    Ballara S; Taylor PC; Reusch P; Marmé D; Feldmann M; Maini RN; Paleolog EM
    Arthritis Rheum; 2001 Sep; 44(9):2055-64. PubMed ID: 11592367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis.
    Hitchon CA; Alex P; Erdile LB; Frank MB; Dozmorov I; Tang Y; Wong K; Centola M; El-Gabalawy HS
    J Rheumatol; 2004 Dec; 31(12):2336-46. PubMed ID: 15570632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin-cleaved osteopontin is increased in urine of patients with rheumatoid arthritis.
    Shio K; Kobayashi H; Asano T; Saito R; Iwadate H; Watanabe H; Sakuma H; Segawa T; Maeda M; Ohira H
    J Rheumatol; 2010 Apr; 37(4):704-10. PubMed ID: 20156944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis.
    van der Helm-van Mil AH; van der Kooij SM; Allaart CF; Toes RE; Huizinga TW
    Ann Rheum Dis; 2008 Jun; 67(6):769-74. PubMed ID: 17965124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC; Chung SJ; Park YB; Lee SK
    Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis.
    van Eijk IC; Tushuizen ME; Sturk A; Dijkmans BA; Boers M; Voskuyl AE; Diamant M; Wolbink GJ; Nieuwland R; Nurmohamed MT
    Ann Rheum Dis; 2010 Jul; 69(7):1378-82. PubMed ID: 19919943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum amyloid A in the assessment of early inflammatory arthritis.
    Cunnane G; Grehan S; Geoghegan S; McCormack C; Shields D; Whitehead AS; Bresnihan B; Fitzgerald O
    J Rheumatol; 2000 Jan; 27(1):58-63. PubMed ID: 10648018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis.
    Hartgring SA; van Roon JA; Wenting-van Wijk M; Jacobs KM; Jahangier ZN; Willis CR; Bijlsma JW; Lafeber FP
    Arthritis Rheum; 2009 Sep; 60(9):2595-605. PubMed ID: 19714586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor.
    Radstake TR; Sweep FC; Welsing P; Franke B; Vermeulen SH; Geurts-Moespot A; Calandra T; Donn R; van Riel PL
    Arthritis Rheum; 2005 Oct; 52(10):3020-9. PubMed ID: 16200611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is interleukin-18 useful for monitoring rheumatoid arthritis?
    Bokarewa M; Hultgren O
    Scand J Rheumatol; 2005; 34(6):433-6. PubMed ID: 16393763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy.
    Singh R; Aggarwal A; Misra R
    J Rheumatol; 2007 Nov; 34(11):2285-90. PubMed ID: 17937463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 10 inhibits interleukin 6 production and acute phase response in rheumatoid arthritis.
    Lacki JK; Klama K; Porawska W; Mackiewicz SH; Müller W; Wiktorowicz K
    Arch Immunol Ther Exp (Warsz); 1995; 43(1):11-4. PubMed ID: 8744678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.